CervoMed to Present at the 8th International Lewy Body Dementia Conference
CervoMed (NASDAQ: CRVO) has announced that it will present topline results from its Phase 2b RewinD-LB study at the 8th International Lewy Body Dementia Conference (ILBDC) in Amsterdam on January 31, 2025. The study focuses on neflamapimod treatment for dementia with Lewy bodies (DLB).
The presentation, titled 'Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB),' will be delivered by Dr. John Alam, CEO and Co-Principal Investigator of the study, during Symposium VIII-Therapy at 13:30 CET / 7:30 ET. The initial topline results were previously disclosed on December 10, 2024.
CervoMed (NASDAQ: CRVO) ha annunciato che presenterà i risultati preliminari del suo studio RewinD-LB di fase 2b alla 8ª Conferenza Internazionale sulla Demenza a Corpi di Lewy (ILBDC) ad Amsterdam il 31 gennaio 2025. Lo studio si concentra sul trattamento con neflamapimod per la demenza con corpi di Lewy (DLB).
La presentazione, intitolata 'Risultati di efficacia e sicurezza dello studio clinico di fase 2b RewinD-LB con neflamapimod nella demenza con corpi di Lewy (DLB),' sarà tenuta dal Dr. John Alam, CEO e Co-Investigatore principale dello studio, durante il Simposio VIII-Terapia alle 13:30 CET / 7:30 ET. I risultati preliminari erano stati già divulgati il 10 dicembre 2024.
CervoMed (NASDAQ: CRVO) ha anunciado que presentará los resultados preliminares de su estudio RewinD-LB de fase 2b en la 8ª Conferencia Internacional sobre la Demencia de Cuerpos de Lewy (ILBDC) en Ámsterdam el 31 de enero de 2025. El estudio se centra en el tratamiento con neflamapimod para la demencia con cuerpos de Lewy (DLB).
La presentación, titulada 'Resultados de eficacia y seguridad del ensayo clínico de fase 2b RewinD-LB con neflamapimod en la demencia con cuerpos de Lewy (DLB),' será realizada por el Dr. John Alam, CEO y Co-Investigador Principal del estudio, durante el Simposio VIII-Terapia a las 13:30 CET / 7:30 ET. Los resultados preliminares se habían divulgado anteriormente el 10 de diciembre de 2024.
CervoMed (NASDAQ: CRVO)는 2025년 1월 31일 암스테르담에서 열리는 제8회 국제 레위체 치매 회의(ILBDC)에서 2상 RewinD-LB 연구의 주요 결과를 발표할 것이라고 발표했습니다. 이 연구는 레위체가 있는 치매(DLB)에 대한 neflamapimod 치료에 중점을 두고 있습니다.
'레위체가 있는 치매(DLB)에 대한 neflamapimod의 RewinD-LB 2상 임상 시험의 효능 및 안전성 결과'라는 제목의 발표는 연구의 CEO이자 공동 수석 연구자인 Dr. John Alam에 의해 Symposium VIII-Therapy에서 CET 기준 13:30 / ET 기준 7:30에 진행됩니다. 초기 주요 결과는 2024년 12월 10일에 이미 공개된 바 있습니다.
CervoMed (NASDAQ: CRVO) a annoncé qu'il présentera les résultats préliminaires de son étude RewinD-LB de phase 2b lors de la 8e Conférence internationale sur la démence à corps de Lewy (ILBDC) à Amsterdam le 31 janvier 2025. L'étude se concentre sur le traitement par neflamapimod de la démence avec corps de Lewy (DLB).
La présentation, intitulée 'Résultats d'efficacité et de sécurité de l'essai clinique de phase 2b RewinD-LB sur le neflamapimod dans la démence avec corps de Lewy (DLB),' sera faite par Dr. John Alam, PDG et co-enquêteur principal de l'étude, lors du Symposium VIII-Thérapie à 13h30 CET / 7h30 ET. Les résultats préliminaires avaient été divulgués auparavant le 10 décembre 2024.
CervoMed (NASDAQ: CRVO) hat angekündigt, dass es am 31. Januar 2025 auf der 8. Internationalen Lewy-Körper-Demenz-Konferenz (ILBDC) in Amsterdam die vorläufigen Ergebnisse seiner Phase 2b RewinD-LB-Studie präsentieren wird. Die Studie konzentriert sich auf die Behandlung von Demenz mit Lewy-Körpern (DLB) mit neflamapimod.
Die Präsentation mit dem Titel 'Wirksamkeits- und Sicherheitsdaten der Phase-2b-Studie RewinD-LB zu neflamapimod bei Demenz mit Lewy-Körpern (DLB)' wird von Dr. John Alam, CEO und Co-Hauptprüfer der Studie, während Symposium VIII-Therapie um 13:30 Uhr CET / 7:30 Uhr ET gehalten. Die ersten vorläufigen Ergebnisse wurden bereits am 10. Dezember 2024 bekannt gegeben.
- None.
- None.
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here.
Details of the ILBDC presentation are as follow:
Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)
Format: Oral Presentation
Presenter: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB Study
Session Name: Symposium VIII-Therapy
Session Date and Time: Friday, January 31, 2025, 13:30pm CET / 7:30am ET
The details of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ following the presentation.
About CervoMed
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant designed to inhibit p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in certain major neurological disorders.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
What are the key findings from CervoMed's Phase 2b RewinD-LB study (CRVO)?
When and where will CervoMed (CRVO) present its RewinD-LB study results?
What is the focus of CervoMed's neflamapimod clinical trial (CRVO)?
Where can investors access CervoMed's (CRVO) ILBDC presentation details?
